OR 3.44), HAQ, and PASI outcomes with concurrent tirzepatide and biologic initiation, alongside markedly lower CRP (4.2 vs 7.7 mg/L
Eli Lillys retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, remains in Phase 3 TRIUMPH trials as of mid-2026, with NDA submission projected no earlier than Q4 2026
My 'GLP-1 results' and 'Zepbound results' have been profound
Legumes Legumes are the overachievers of the food world
More importantly, a large-scale 3b-phase randomized controlled trial (SURMOUNT-5), which compared semaglutide with tirzepatide in 751 obese adults without type 2 diabetes, explicitly reported that male patients had an average weight loss approximately 6 percentage points lower than female patients after 72 weeks of semaglutide treatment, further verifying that sex is an independent factor affecting semaglutides efficacy [80]